

PROVIDER QUICK POINTS

PROVIDER INFORMATION



September 11, 2018

Pharmacy Benefit Exclusion for Onpattro™ (patisiran) Lipid Complex Intravenous (IV) Injection

Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) is committed to providing subscribers with safe, quality, pharmacy care.

Onpattro™ (patisiran) lipid complex IV injection is a new drug product approved by the Food and Drug Administration (FDA) for Hereditary Amyloidogenic Transthyretin Amyloidosis (hATTR). Upon launch, Onpattro™ (patisiran) will be excluded from pharmacy benefit coverage due to clinician-administered route of administration. Onpattro™ (patisiran) may be available for medical benefit coverage for subscribers who are eligible.

Drug Name
Onpattro™ (patisiran) lipid complex IV injection

Products Impacted

This notice applies to commercial lines of business **and** the following Minnesota Health Care Programs:

- Blue Advantage Prepaid Medical Assistance Program (PMAP)
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

Products Not Impacted

Federal Employee Program (FEP), Platinum Blue and Medicare Supplement subscribers are not impacted.

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.

QP77-18

Distribution: Available on providers.bluecrossmn.com. <https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications>

Blue Cross® and Blue Shield® of Minnesota and Blue Plus® are nonprofit independent licensees of the Blue Cross and Blue Shield Association.

L264R03 (12/13)